Related Experiment Video

Updated: Aug 10, 2025

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.4K

Elevated serum FGF21 levels predict heart failure during hospitalization of STEMI patients after emergency

Lingyun Gu1, Wenxi Jiang1, Wenlong Jiang1

  • 1The Jiangyin Clinical College, Xuzhou Medical University, Jiangyin, Jiangsu, China.

Peerj
|February 13, 2023
PubMed

Insights

Elevated Fibroblast Growth Factor 21 (FGF21) levels predict heart failure in ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI). Higher FGF21 indicates increased risk during hospitalization.

Area of Science:

  • Cardiology
  • Endocrinology
  • Biochemistry

Background:

  • Fibroblast Growth Factor 21 (FGF21) exhibits cardioprotective properties.
  • Its role in heart failure development post-ST-segment elevation myocardial infarction (STEMI) requiring percutaneous coronary intervention (PCI) remains uninvestigated.

Purpose of the Study:

  • To investigate the association between serum FGF21 levels and heart failure development in STEMI patients undergoing emergency PCI.
  • To evaluate FGF21 as a potential predictor of in-hospital heart failure.

Main Methods:

  • A cohort of 348 STEMI patients treated with emergency PCI was analyzed.
  • Serum FGF21 levels were measured using ELISA.
  • Heart failure occurrence and cardiac function were assessed.

Main Results:

  • STEMI patients who developed heart failure had significantly higher serum FGF21 levels.
  • Serum FGF21 strongly correlated with N-terminal precursor B-type natriuretic peptide (NT-proBNP).
  • FGF21 was identified as an independent risk factor for heart failure, with an AUC of 0.816 for prediction.

Conclusions:

  • Elevated serum FGF21 is a strong predictor of heart failure during hospitalization in STEMI patients post-emergency PCI.
  • FGF21 may serve as a valuable biomarker for risk stratification in these patients.
Abstract

Keywords:
Fibroblast growth factor 21Heart failureST-segment elevation myocardial infarction

More Related Videos

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery08:43

Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery

Published on: February 14, 2017

11.1K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

8.6K

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
221
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
19
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
134
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
31